The Vall d’Hebron Institute of Oncology (VHIO) is launching VHIODivulga, a different, more accessible and engaging way of communicating the…
featured news home
For the fourth consecutive year, VHIO is opening applications for its mentoring programme, VHIO4STEM. During the programme, 22 students in…
Results of final overall survival analysis from the global, randomized phase 3 MATTERHORN clinical trial show that adding perioperative durvalumab…
An international study led by VHIO within the ENIGMA consortium has analysed 166 variants in and around exon 18 of…
The European Society for Medical Oncology (ESMO) announced the professionals selected for its 2026 Fellowship Programme, including Maria Vieito and…
Published in The Lancet, results of the phase III LITESPARK-011 clinical trial point to the combination of belzutifan plus lenvatinib…
First results from the multicenter FUSOMAP project, led by VHIO, support the potential use of Fusobacterium as a prognostic and…
CD Terrassa Hockey has donated more than 3.000€ to the Vall d’Hebron Institute of Oncology (VHIO) to support research into…
Results from the international, randomized phase III LITESPARK-022 study show that the addition of hypoxia-inducible factor-2 alpha (HIF-2 α) inhibitor…
The Iker Association has donated 10.000 euros to the Vall d’Hebron Institute of Oncology (VHIO) to continue research into myxoid…
